SciVision Biotech (TPE:1786) received approval from the Japan Patent Office for a new method of making auto-cross linked hyaluronic acid gel.
The patented process will boost product performance, broaden the company's offerings, and boost competitiveness.
The biotech company expects the development to have a positive impact on its business and shareholders, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.